David Ross, Senior Medical Director, Lung Transplantation and Molecular Diagnostics at Natera, shared a post on LinkedIn:
“Prospera Lung test (donor-derived cell-free DNA) surveillance permits a safe reduction in protocol invasive trans-bronchial biopsies after Lung Transplant.
Our congratulations to the Ohio State Lung Transplant Program for conducting this pivotal and forward-thinking Quality Assurance and Performance Improvement initiative (QAPI) and advancing personalized medicine for these challenging patients!”
Title: Surveillance Donor-derived Cell-free DNA Allows for the Safe Reduction in Protocol Transbronchial Biopsies After Lung Transplantation
Authors: Kashika Goyal, David J. Ross, Bronwyn Small, Namita Trikannad, Sangeeta Bhorade, Justin Rosenheck
You can read the full article in Transplantation Direct.
